Video

Addressing Frequent Cardiovascular Risk Factors in Visually Impaired Patients

Author(s):

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

Research presented this week at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Sessions showed that patients with visual impairment are notably more likely to present with cardiovascular disease and risk factors for it than the general population.

In new data from US Centers for Disease Control and Prevention (CDC) investigators, presented by Elizabeth Lundeen, PhD, MPH, of the Division of Diabetes Translation at the CDC, patients with visual impairment who participated in a 2018 national health survey showed greater likelihood for more than a half-dozen risk factors associated with cardiovascular disease and major adverse cardiovascular events.

Among the most prevalent findings included a 46% greater likelihood of diabetes in visually-impaired persons versus the general population (associated prevalence ratio [aPR], 1.46; 95% CI, 1.32 - 1.63), and 36% greater likelihood of smoking status (aPR, 1.36; 95% CI, 1.24 - 1.48).

In an interview with HCPLive during ARVO 2021, Lundeen discussed how the observed risk factors—which additionally included obesity and hypertension, among others—closely overlap between cardiovascular disease and age-related macular degeneration (AMD), the leading cause of blindness in the US.

“There’s just a strong correlation between cardiovascular health and vision health,” she explained.

Lundeen also discussed how the findings, which only cement the linkage between health- and lifestlye-related cardiovascular risk factors and worsened vision health, could provide guidance for experts to be “creative” with their chronic disease-preventive solutions.

“I think there are opportunities to better integrate vision screening and attention to vision health within routine clinical care—whether it’s from a general practitioner, an endocrinologist, a cardiologist,” she said. “As well, there are opportunities to integrate chronic disease prevention into rehabilitative vision services.”

Related Videos
Investigating Briquilimab’s Efficacy and Safety for CSU, with Thomas Casale, MD
What to Look Forward to at the American Academy of Dermatology Annual Meeting 2025
Ahmad Anouti, MD | Credit: UT Southwestern
Improving Care for ISM With Better Diagnosis, Disease Characterization, with Thanai Pongdee, MD
Skin of Color Savvy: Hair Loss Misconceptions, Clinical Insights, and Management, with Janiene Luke, MD, and Victoria Barbosa, MD, MPH
John Barbieri, MD, MBA | Credit: Brigham and Women's Hospital
Achieving Chronic Spontaneous and Inducible Urticaria Control With Barzolvolimab, with Martin Metz, MD
Scott Commins, MD, PhD I Credit: UNC School of Medicine
Optimizing ISM Treatment Beyond Approval, with Vito Sabato, MBBS
Updated Treatment Strategies for Pediatric Atopic Dermatitis in 2025, with Ama Alexis, MD
© 2025 MJH Life Sciences

All rights reserved.